How did SABS's Q2 2024 EPS forecast compare to past trends?
4/10/2025 04:32am
Aime
SAB Biotherapeutics (SABS) is forecasted to report an EPS of -$1.13 for Q2 2024, which is worse than the -$0.79 reported in Q2 202312. This indicates a potential decline in the company's earnings, suggesting a negative outlook for the period.
1/2
Source:
1.
SABS EPS in the past five years with focus on Q2 2024
more
less
Explore
Screener
What are the best stocks to buy now?
Analysis
Aple Rating chart
Learn
Advanced technical indicators and how they are calculated and utilized